Proactive investorsLogo Proactive Investors UK Website

Search field
Get Adobe Flash Player Download
Flash
Player ►

And
Enable
Javascript

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: ASX
Sector: Pharma & Biotech
Epic: QRX
News: Latest news
Web Site: QRxPharma Ltd
Other Articles: 06-01-201010-12-200913-11-2009

RSS - Subscribe to the News Today on Proactive UK ▼

Thursday March 18, 08:01SmartFocus, Amphion Innovations and National Milk Records confirmed for March 18 Forum

The presentations will start at 6:00pm and finish at approx 7:30pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive NA ▼

Thursday March 18, 01:14Cisco remains at the forefront of internet infrastructure

The stock has recently managed to breakout above the long term resistance found at the $25 level which should now provide support for any pullback before the share price drives higher

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Monday March 15, 08:01China's growth boosting commodity prices

The latest economic figures from China have put pressure on the dollar and boosted a number of high-yielding currencies, including the Australian dollar and the South African rand.

FULL ARTICLE ►
QRxPharma Ltd

QRxPharma Ltd

QRxPharma Limited (ASX: QRX; OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders.  The Company’s lead products comprise a patented combination of existing drugs, with a well-defined path to regulatory approval and sales.  QRxPharma’s lead drug compound, MoxDuo™ IR (Q8003IR), began Phase III clinical trials in November 2007. The Company’s preclinical and clinical pipeline includes other technologies in the fields of neurodegenerative disease and venomics.

 

CLICK HERE FOR FULL ANALYSIS OF QRXPHARMA LTD
Monday, October 12, 2009

QRxPharma inks agreement with TSX-listed Patheon

by Andrew McCrea company news image

QRxPharma Limited (ASX: QRX, OTCQX: QRXPY) has added further value for shareholders, inking an agreement with Toronto listed Patheon Inc. (TSX: PTI) to manufacture clinical supplies of QRxPharma’s Dual-Opioid™ formulation (MoxDuo™CR).

Patheon is a leading contract drug developer and manufacturing for the pharmaceutical and biotechnology industries.

Patheon has a market capitalisation of C$180 million and revenues of US$717 million.

MoxDuo™CR is designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic).

The most advanced pain treatment product, MoxDuo™IR (immediate release formulation), is now in Phase 3 trials and scheduled for New Drug Application (NDA) filing with the US Food and Drug Administration in 2010.

“The Patheon relationship represents a major step forward for QRxPharma that rounds out our platform of MoxDuo™ products,” said Dr. John Holaday managing director.

“We are targeting a twice daily dosage with MoxDuo™ CR, and we anticipate our initial Phase 1 studies will begin this year to evaluate the pharmacokinetic profile of this patented formulation, Holaday said.”

QRxPharma’s formulation of MoxDuo™CR is anticipated to complete clinical trials in 2012.

The company believes MoxDuo™CR will deliver clinical benefits similar to those clinically demonstrated with MoxDuo™IR – fewer side effects and superior pain relief.

AddThis Feed Button
Register here to be notified of Proactiveinvestors One2One Forums.

Other QRxPharma Ltd news

More news ►

Investors interested in QRxPharma Ltd recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.